In this sense, our tool could greatly interest clinicians in patients with immune dysfunction (CD4+ lymphocyte count < 500 cells/mm3, CD4/CD8 ratio < 0.9, CD8+ lymphocyte count > 1000 cells/mm3), despite virological control of HIV infection with ART, before switching to a 2DR with DTG plus 3TC. The gene discussed is CD8A; the disease is immune system disorder.